EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EyePoint is viewed positively because DURAVYU showed compelling secondary endpoint signals, including a 42% reduction in treatment burden, 76% of patients supplement-free through Week 32, and a 4-micron central subfield thickness advantage versus aflibercept at Week 56, all consistent with meaningful durability and an improved patient experience. Although LUGANO missed its Phase 3 non-inferiority primary endpoint, management’s confidence in the asset, combined with a favorable safety profile and strong anatomic outcomes, supports the possibility of a regulatory path if LUCIA is successful in 4Q26. The company’s broader pipeline, including EYP-2301, and its focus on disease-modifying, lower-burden retinal therapies also support long-term value creation and a clinically relevant commercial opportunity.

EyePoint is facing a fundamentally weaker outlook because LUGANO missed its prespecified primary non-inferiority endpoint in the ITT population, undermining confidence in DURAVYU and removing the clear two-positive-Phase-3 path investors had expected. The negative readthrough is amplified by the unusual asymmetric cohort and the lingering question of whether the FDA would rely on LUCIA alone, with data not expected until 4Q26 and regulatory uncertainty now substantially higher. Financially, the downside case assumes no value for clinical programs, leaving support only from cash and Yutiq revenue, while the company may need additional capital before profitability, creating dilution risk.